{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:10:24Z","timestamp":1791951024598,"version":"4.3.4"},"reference-count":97,"publisher":"American Chemical Society (ACS)","issue":"21","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277131"],"award-info":[{"award-number":["22277131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CDK9 is a pivotal kinase in transcriptional regulatory networks. It has emerged as a promising anticancer target because of its critical role in regulating key oncoproteins such as MYC and MCL-1. While CDK9 inhibitors have shown preclinical efficacy, their clinical translation faces challenges, including narrow therapeutic windows, limited monotherapy effectiveness, and drug resistance. Targeted protein degradation (TPD) strategies, particularly PROTACs that induce CDK9 ubiquitination and degradation, offer a promising solution. These PROTACs exhibit potent and sustained antitumor effects, effectively overcoming resistance mechanisms such as MYC upregulation. Additionally, innovative approaches employing heterobifunctional molecules across various modalities have been extensively explored to target CDK9, expanding the therapeutic potential through multiple mechanisms. These advances hold promise for establishing a new paradigm in the treatment of transcriptionally addicted cancers.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02127","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:30:08Z","timestamp":1761399008000},"page":"22095-22115","source":"Crossref","is-referenced-by-count":6,"title":["Beyond Inhibition:\nRecent Advances of Heterobifunctional\nMolecules Targeting CDK9"],"prefix":"10.1021","volume":"68","author":[{"given":"Junzhe","family":"Yin","sequence":"first","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences , , ,","place":["Shanghai, China, 201203"]},{"name":"University of Chinese Academy of Sciences , ,","place":["Beijing, China, 100049"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6062-6708","authenticated-orcid":true,"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Materia Medica, Chinese Academy of Sciences , , ,","place":["Shanghai, China, 201203"]},{"name":"University of Chinese Academy of Sciences , ,","place":["Beijing, China, 100049"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"4","key":"2026073103135912400_cit1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional Addiction in Cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"2026073103135912400_cit2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: A Comprehensive\nReview of Its Biology, and Its Role as a Potential Target for Anti-Cancer\nAgents","volume":"11","author":"Anshabo","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"2026073103135912400_cit3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-Dependent\nKinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"issue":"1","key":"2026073103135912400_cit4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell\nCycle Control in Cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell\nBiol."},{"issue":"1","key":"2026073103135912400_cit5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting\nTranscription Cycles in Cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"2026073103135912400_cit6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/molecules25040838","article-title":"P-TEFb as\nA Promising Therapeutic Target","volume":"25","author":"Fujinaga","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"2026073103135912400_cit7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","article-title":"P-TEFb:\nThe Master Regulator of Transcription\nElongation","volume":"83","author":"Fujinaga","year":"2023","journal-title":"Mol. Cell"},{"issue":"2","key":"2026073103135912400_cit8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1039\/C6MB00387G","article-title":"The Emerging\nPicture of CDK9\/P-TEFb:\nMore than 20 Years of Advances since PITALRE","volume":"13","author":"Paparidis","year":"2017","journal-title":"Mol. Biosyst."},{"issue":"9","key":"2026073103135912400_cit9","doi-asserted-by":"publisher","first-page":"6356","DOI":"10.1021\/acs.jmedchem.1c02190","article-title":"Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery\nEfforts","volume":"65","author":"Xie","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026073103135912400_cit10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1021\/acs.biochem.2c00609","article-title":"Addressing Transcriptional\nDysregulation in Cancer\nthrough CDK9 Inhibition","volume":"62","author":"Toure","year":"2023","journal-title":"Biochemistry"},{"key":"2026073103135912400_cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116470","article-title":"CDK9 Inhibitors for\nthe Treatment of Solid Tumors","volume":"229","author":"Mo","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"2026073103135912400_cit12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","article-title":"Targeting Cyclin-Dependent\nKinase\n9 in Cancer Therapy","volume":"43","author":"Shen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"7","key":"2026073103135912400_cit13","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1021\/acs.jmedchem.4c00312","article-title":"Recent Discovery and Development of Inhibitors That Target CDK9 and\nTheir Therapeutic Indications","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026073103135912400_cit14","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2219470","article-title":"Targeting CDK9 with Selective Inhibitors\nor Degraders in Tumor Therapy: An Overview of Recent Developments","volume":"24","author":"Xiao","year":"2023","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"2026073103135912400_cit15","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2020.12.008","article-title":"Targeting Pan-Essential\nGenes in Cancer: Challenges and Opportunities","volume":"39","author":"Chang","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"2026073103135912400_cit16","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: Past, Present and Future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"2026073103135912400_cit17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A Selective BCL-XL\nPROTAC Degrader Achieves Safe and Potent Antitumor Activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"20","key":"2026073103135912400_cit18","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474\u2500a\nPotent, Selective, and Orally Bioavailable IRAK4 Degrader for the\nTreatment of Autoimmune Diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026073103135912400_cit19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2010.10.004","article-title":"Pausing of RNA Polymerase II Disrupts DNA-Specified\nNucleosome Organization to Enable Precise Gene Regulation","volume":"143","author":"Gilchrist","year":"2010","journal-title":"Cell"},{"issue":"12","key":"2026073103135912400_cit20","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1016\/j.cell.2021.04.022","article-title":"The PP2A-Integrator-CDK9\nAxis Fine-Tunes Transcription and Can Be Targeted Therapeutically\nin Cancer","volume":"184","author":"Vervoort","year":"2021","journal-title":"Cell"},{"issue":"3","key":"2026073103135912400_cit21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1128\/MMBR.00011-06","article-title":"The Yin and Yang\nof P-TEFb Regulation: Implications\nfor Human Immunodeficiency Virus Gene Expression and Global Control\nof Cell Growth and Differentiation","volume":"70","author":"Zhou","year":"2006","journal-title":"Microbiol.\nMol. Biol. Rev."},{"issue":"4","key":"2026073103135912400_cit22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The Bromodomain Protein Brd4 Is a Positive Regulatory Component of\nP-TEFb and Stimulates RNA Polymerase II-Dependent Transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol. Cell"},{"issue":"8","key":"2026073103135912400_cit23","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/leu.2009.33","article-title":"New Insights to the MLL Recombinome of Acute Leukemias","volume":"23","author":"Meyer","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2026073103135912400_cit24","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020990","article-title":"MYC and Transcription\nElongation","volume":"4","author":"Rahl","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2026073103135912400_cit25","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06535","article-title":"Compensatory\nInduction of MYC Expression by Sustained CDK9 Inhibition via a BRD4-Dependent\nMechanism","volume":"4","author":"Lu","year":"2015","journal-title":"eLife"},{"issue":"10","key":"2026073103135912400_cit26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 Family Proteins in Mitochondrial\nApoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"2026073103135912400_cit27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-Stroma\nInteractions and Re-Sensitizes Acute Myeloid Leukemia to BCL-2 Inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2026073103135912400_cit28","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/embor.2010.153","article-title":"Cyclin-dependent Kinase 9\u2013Cyclin\nK Functions in the Replication Stress Response","volume":"11","author":"Yu","year":"2010","journal-title":"EMBO Rep."},{"issue":"2","key":"2026073103135912400_cit29","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1021\/acs.jmedchem.4c02441","article-title":"Structure-Guided Discovery of Novel\nN4-(Substituted Thiazol-2-Yl)-N2-(4-Substituted Phenyl)Pyrimidine-2,4-Diamines\nas Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026073103135912400_cit30","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.9.6.1143","article-title":"Flavopiridol (L86 8275; NSC 649890),\na New Kinase Inhibitor for Tumor Therapy","author":"Sedlacek","year":"1996","journal-title":"Int.\nJ. Oncol."},{"issue":"12","key":"2026073103135912400_cit31","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical Activity of Alvocidib (Flavopiridol) in Acute\nMyeloid Leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk. Res."},{"issue":"7","key":"2026073103135912400_cit32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I\nClinical and Pharmacokinetic\nStudy of a Novel Schedule of Flavopiridol in Relapsed or Refractory\nAcute Leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"key":"2026073103135912400_cit33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117875","article-title":"Discovery and Optimization of Novel Tetrahydrothiazolopyridine-Based\nPyrimidines as Highly Potent Cyclin-Dependent Kinase 9 (CDK9) Inhibitors","volume":"296","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"Supplement\n1","key":"2026073103135912400_cit34","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1182\/blood-2022-167203","article-title":"Safety, Tolerability,\nPharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent\nKinase-9 (CDK9) Inhibitor AZD4573 in Relapsed\/Refractory Hematological\nMalignancies: A Phase 1 First-in-Human Study","volume":"140","author":"Brummendorf","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"2026073103135912400_cit35","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1182\/blood-2022-165979","article-title":"Phase 1b\/2a\nStudy of\nAZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed\/Refractory\nDiffuse Large B-Cell Lymphoma (r\/r DLBCL): Results from Dose-Escalation","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"2026073103135912400_cit36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/hon.3164_425","article-title":"Encouraging Complete\nResponses (CRs) with CDK9 Inhibitor AZD4573 in Patients (Pts) with\nRelapsed\/Refractory (r\/r) Peripheral T-Cell Lymphoma (PTCL): Early\nTrial Analysis","volume":"41","author":"Zinzani","year":"2023","journal-title":"Hematological Oncology"},{"issue":"7","key":"2026073103135912400_cit37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-Human Dose-Escalation Study of Cyclin-Dependent\nKinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows\nEarly Signs of Clinical Efficacy","volume":"28","author":"Diamond","year":"2022","journal-title":"Clin. Cancer\nRes."},{"issue":"Supplement 1","key":"2026073103135912400_cit38","doi-asserted-by":"publisher","first-page":"9454","DOI":"10.1182\/blood-2022-167651","article-title":"Enitociclib (VIP152\/Formerly BAY1251152)\nIs a Selective\nand Active CDK9 Inhibitor: Preliminary Safety and Early Signs of Efficacy\nin Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic\nLeukemia (CLL)","volume":"140","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"2026073103135912400_cit39","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO.2024.42.16_suppl.3102","article-title":"Study Update of\nthe Oral CDK9 Inhibitor KB-0742 in Relapsed or Refractory Transcriptionally\nAddicted Advanced Solid Tumors","volume":"42","author":"Villalona-Calero","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8_Supplement","key":"2026073103135912400_cit40","doi-asserted-by":"publisher","first-page":"CT173","DOI":"10.1158\/1538-7445.AM2023-CT173","article-title":"Abstract CT173:\nA Phase 1, Open-Label, Multicenter, Dose-Escalation Study of PRT2527,\na Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Adult Patients (Pts)\nwith Advanced Solid Tumors","volume":"83","author":"Henry","year":"2023","journal-title":"Cancer Res."},{"issue":"12_Supplement","key":"2026073103135912400_cit41","doi-asserted-by":"publisher","first-page":"C164","DOI":"10.1158\/1535-7163.TARG-23-C164","article-title":"Abstract C164: A Phase 1 Dose-Escalation\nStudy of PRT2527,\na Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Adult Patients with\nAdvanced Solid Tumors: An Updated Analysis","volume":"22","author":"Patel","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"Supplement 1","key":"2026073103135912400_cit42","doi-asserted-by":"publisher","first-page":"9473","DOI":"10.1182\/blood-2022-159844","article-title":"First in Human\n(FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase\n9 (CDK9) Inhibitor, in Patients with Relapsed\/Refractory (r\/r) Hematologic\nMalignancies","volume":"140","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"2026073103135912400_cit43","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2024-198686","article-title":"Phase 2a Study of\nSLS009, a Highly Selective CDK9 Inhibitor,\nin Combination with Azacitidine and Venetoclax for Relapsed\/Refractory\nAcute Myeloid Leukemia after Prior Venetoclax Treatment","volume":"144","author":"Zeidner","year":"2024","journal-title":"66th ASH Annu. Meet. Abstr."},{"issue":"24","key":"2026073103135912400_cit44","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That\nEnables Short Duration of Target Engagement for the Treatment of Hematological\nMalignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026073103135912400_cit45","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 Is a Highly\nSelective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis\nin Hematologic Cancer Cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"2026073103135912400_cit46","doi-asserted-by":"publisher","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for\nthe Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor\nVIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment\nof Cancer","volume":"64","author":"Lu\u0308cking","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026073103135912400_cit47","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"VIP152 Is\na Selective CDK9 Inhibitor with Pre-Clinical\nin Vitro and in Vivo Efficacy in Chronic Lymphocytic Leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"issue":"11","key":"2026073103135912400_cit48","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/2767-9764.CRC-23-0219","article-title":"Enitociclib, a Selective CDK9 Inhibitor,\nInduces Complete Regression of MYC+ Lymphoma by Downregulation of\nRNA Polymerase II Mediated Transcription","volume":"3","author":"Frigault","year":"2023","journal-title":"Cancer\nRes. Commun."},{"issue":"1","key":"2026073103135912400_cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100050","article-title":"Enitociclib,\na Selective CDK9 Inhibitor: In Vitro and in Vivo Preclinical Studies\nin Multiple Myeloma","volume":"2","author":"Tran","year":"2025","journal-title":"Blood Neoplasia"},{"key":"2026073103135912400_cit50","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2023-180567","article-title":"Targeting\nCDK9 in KMT2A-Rearranged Infant Leukemia:\nEvidence for Activity and Drug Synergy with Enitociclib","volume":"142","author":"Sharma","year":"2023","journal-title":"Blood"},{"issue":"7_Supplement","key":"2026073103135912400_cit51","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1158\/1538-7445.AM2023-1558","article-title":"Abstract 1558:\nTargeting CDK9 via the Small-Molecule Inhibitor Enitociclib as a Therapeutic\nStrategy to Treat MYCN-Amplified Rhabdomyosarcoma and Neuroblastoma\nin Children","volume":"83","author":"Tran","year":"2023","journal-title":"Cancer Res."},{"issue":"12_Supplement","key":"2026073103135912400_cit52","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1538-7445.AM2022-1859","article-title":"Abstract 1859: VIP152,\na Selective CDK9 Inhibitor, Demonstrates Sensitivity in Gynecologic\nCell Lines That Are Cisplatin Sensitive or Resistant and Delivers\nin Vivo Antitumor Efficacy","volume":"82","author":"Frigault","year":"2022","journal-title":"Cancer Res."},{"issue":"23","key":"2026073103135912400_cit53","doi-asserted-by":"publisher","first-page":"15629","DOI":"10.1021\/acs.jmedchem.3c01233","article-title":"Discovery of KB-0742, a Potent, Selective,\nOrally Bioavailable\nSmall Molecule Inhibitor of CDK9 for MYC-Dependent Cancers","volume":"66","author":"Freeman","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12_Supplement","key":"2026073103135912400_cit54","doi-asserted-by":"publisher","first-page":"P237","DOI":"10.1158\/1535-7163.TARG-21-P237","article-title":"Abstract P237: PRT2527\nIs a Potent and Selective CDK9 Inhibitor That Demonstrates Anti-Cancer\nActivity in Preclinical Models of Hematological Malignancies and Solid\nTumors with MYC Amplification","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"12_Supplement","key":"2026073103135912400_cit55","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1158\/1538-7445.AM2022-5471","article-title":"Abstract\n5471: PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9\n(CDK9) Inhibitor, Is Active in Preclinical Models of Prostate Cancer","volume":"82","author":"Federici","year":"2022","journal-title":"Cancer Res."},{"issue":"8","key":"2026073103135912400_cit56","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","article-title":"Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent\nKinase Inhibitor","volume":"9","author":"Parry","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"54","key":"2026073103135912400_cit57","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically Induced Degradation of CDK9 by a Proteolysis Targeting\nChimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"key":"2026073103135912400_cit58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128061","article-title":"Aminopyrazole\nBased CDK9 PROTAC Sensitizes Pancreatic Cancer Cells to Venetoclax","volume":"43","author":"King","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"2026073103135912400_cit59","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.66","article-title":"Wogonin and Related Natural Flavones\nAre Inhibitors of CDK9 That Induce Apoptosis in Cancer Cells by Transcriptional\nSuppression of Mcl-1","volume":"2","author":"Polier","year":"2011","journal-title":"Cell Death Dis."},{"key":"2026073103135912400_cit60","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","article-title":"Discovery of Wogonin-Based\nPROTACs against CDK9 and Capable of Achieving Antitumor Activity","volume":"81","author":"Bian","year":"2018","journal-title":"Bioorganic Chem."},{"issue":"2","key":"2026073103135912400_cit61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological Perturbation of CDK9 Using Selective\nCDK9 Inhibition or Degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"2026073103135912400_cit62","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/jm0305568","article-title":"N -(Cycloalkylamino)Acyl-2-Aminothiazole Inhibitors of Cyclin-Dependent\nKinase 2. N -[5-[[[5-(1,1-Dimethylethyl)-2-Oxazolyl]Methyl]Thio]-2-Thiazolyl]-4-\nPiperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective\nAntitumor Agent","volume":"47","author":"Misra","year":"2004","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026073103135912400_cit63","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.3390\/ijms23105476","article-title":"Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive\nBreast Cancer","volume":"23","author":"Noblejas-Lo\u0301pez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2026073103135912400_cit64","unstructured":"Barsanti, P. A.; Hu, C.; et al.\n          Pyridine and Pyrazine\nDerivatives as Protein Kinase Modulators. WO2011012661A1, February 3, 2011."},{"key":"2026073103135912400_cit65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of Selective Mono or Dual PROTAC Degrader\nProbe of CDK Isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"2026073103135912400_cit66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery\nof Selective CDK9 Degraders with Enhancing Antiproliferative Activity\nthrough PROTAC Conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2026073103135912400_cit67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114792","article-title":"Modulation\nof FLT3-ITD and CDK9 in Acute Myeloid Leukaemia Cells by Novel Proteolysis\nTargeting Chimera (PROTAC)","volume":"243","author":"R\u030cezni\u0301c\u030ckova\u0301","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026073103135912400_cit68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115342","article-title":"Bifunctional Degraders\nof Cyclin Dependent Kinase 9 (CDK9): Probing the Relationship between\nLinker Length, Properties, and Selective Protein Degradation","volume":"254","author":"Tokarski","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"2026073103135912400_cit69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2022.107741","article-title":"The Synthesis of PROTAC\nMolecule\nand New Target KAT6A Identification of CDK9 Inhibitor iCDK9","volume":"34","author":"Ao","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"2026073103135912400_cit70","unstructured":"AYINDE, O. R.; Fuchs, J. R.; et al.\n          Cyclin-Dependent Kinase 9 (Cdk9) Degraders\nand Methods of Using Thereof. WO2023192534A1. October\n5, 2023."},{"key":"2026073103135912400_cit71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115774","article-title":"Discovery\nof Novel Flavonoid-Based\nCDK9 Degraders for Prostate Cancer Treatment via a PROTAC Strategy","volume":"260","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026073103135912400_cit72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116972","article-title":"CDK9 Targeting\nPROTAC L055 Inhibits ER\u03b1-Positive Breast Cancer","volume":"177","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"19","key":"2026073103135912400_cit73","doi-asserted-by":"publisher","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of Potent\nand Selective CDK9 Degraders for Targeting Transcription Regulation\nin Triple-Negative Breast Cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026073103135912400_cit74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107876","article-title":"Discovery\nof a Potent, Selective and Orally Bioavailable CDK9 Degrader for Targeting\nTranscription Regulation in Triple-Negative Breast Cancer","volume":"153","author":"Nie","year":"2024","journal-title":"Bioorganic Chem."},{"issue":"1","key":"2026073103135912400_cit75","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.1038\/s41467-024-54354-3","article-title":"CDK9 Recruits HUWE1 to Degrade RAR\u03b1\nand Offers Therapeutic\nOpportunities for Cutaneous T-Cell Lymphoma","volume":"15","author":"Luo","year":"2024","journal-title":"Nat. Commun."},{"key":"2026073103135912400_cit76","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1021\/acs.jmedchem.4c01621","article-title":"Identification of a\nPotent and Selective CDK9 Degrader as a Targeted Therapeutic Option\nfor the Treatment of Small-Cell Lung Cancer","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026073103135912400_cit77","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.22.639565","article-title":"CDK9 Degradation Inhibits Gastroesophageal\nCancer Growth and Overcomes\nRadiation Resistance by Increasing Chromatin Accessibility and Downregulating\nYAP1\/TEAD Signaling","author":"Zhang","year":"2025","journal-title":"bioRxiv"},{"issue":"4","key":"2026073103135912400_cit78","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.chembiol.2025.03.001","article-title":"Targeted Degradation of CDK9 Potently\nDisrupts the\nMYC-Regulated Network","volume":"32","author":"Toure","year":"2025","journal-title":"Cell Chem. Biol."},{"issue":"2","key":"2026073103135912400_cit79","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.chembiol.2020.10.001","article-title":"Modulating Androgen Receptor-Driven\nTranscription in Prostate Cancer with Selective CDK9 Inhibitors","volume":"28","author":"Richters","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"749","key":"2026073103135912400_cit80","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abn2707","article-title":"The Drug\nEfflux Pump MDR1 Promotes Intrinsic and Acquired\nResistance to PROTACs in Cancer Cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci.\nSignal."},{"issue":"16","key":"2026073103135912400_cit81","doi-asserted-by":"publisher","first-page":"11034","DOI":"10.1021\/acs.jmedchem.2c00257","article-title":"Discovery\nof Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting\nTranscriptional Addiction in Prostate Cancer","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026073103135912400_cit82","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1016\/j.apsb.2025.03.047","article-title":"First ATG101-Recruiting\nSmall Molecule Degrader for Selective CDK9\nDegradation via Autophagy\u2013Lysosome Pathway","volume":"15","author":"Zhong","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"18","key":"2026073103135912400_cit83","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1021\/acs.jmedchem.3c00828","article-title":"Degradation\nof Cyclin-Dependent Kinase\n9\/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain\n3 Beta-Recruiting Coumarin Analogs","volume":"66","author":"Zeng","year":"2023","journal-title":"J. Med.\nChem."},{"issue":"7781","key":"2026073103135912400_cit84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-Selective Lowering of Mutant HTT Protein by\nHTT\u2013LC3 Linker Compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"issue":"9","key":"2026073103135912400_cit85","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1365-2443.2010.01433.x","article-title":"MBSJ MCC Young Scientist Award 2009 REVIEW: Selective\nAutophagy Regulates Various Cellular Functions","volume":"15","author":"Komatsu","year":"2010","journal-title":"Genes Cells"},{"issue":"1","key":"2026073103135912400_cit86","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.apsb.2024.09.003","article-title":"DiPTAC: A Degradation Platform via\nDirectly Targeting Proteasome","volume":"15","author":"Tu","year":"2025","journal-title":"Acta Pharm. Sin.\nB"},{"issue":"2","key":"2026073103135912400_cit87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.chembiol.2023.01.004","article-title":"Piperlongumine\nConjugates Induce Targeted Protein Degradation","volume":"30","author":"Pei","year":"2023","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"2026073103135912400_cit88","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1038\/s41467-023-40244-7","article-title":"DNA Framework-Engineered Chimeras\nPlatform Enables Selectively Targeted Protein Degradation","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"issue":"30","key":"2026073103135912400_cit89","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.1002\/anie.201403236","article-title":"Single-Particle Tracking and Modulation\nof Cell Entry Pathways of\na Tetrahedral DNA Nanostructure in Live Cells","volume":"53","author":"Liang","year":"2014","journal-title":"Angew. Chem., Int. Ed."},{"issue":"6717","key":"2026073103135912400_cit90","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl5361","article-title":"Relocalizing Transcriptional Kinases\nto Activate Apoptosis","volume":"386","author":"Sarott","year":"2024","journal-title":"Science"},{"issue":"11","key":"2026073103135912400_cit91","doi-asserted-by":"publisher","first-page":"9074","DOI":"10.1021\/jacs.5c00131","article-title":"Dual-Action-Only\nPROTACs","volume":"147","author":"Dutta","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"2026073103135912400_cit92","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC Targeting by OMO-103 in Solid Tumors: A Phase 1 Trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"2026073103135912400_cit93","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","article-title":"MYC in Cancer: From Undruggable Target\nto Clinical\nTrials","volume":"24","author":"Whitfield","year":"2025","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"1","key":"2026073103135912400_cit94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in Cancer: Current\nStatus and Perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"2026073103135912400_cit95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","article-title":"Co-Targeting BCL-XL\nand MCL-1 with\nDT2216 and AZD8055 Synergistically Inhibit Small-Cell Lung Cancer\nGrowth without Causing on-Target Toxicities in Mice","volume":"9","author":"Khan","year":"2023","journal-title":"Cell Death Discovery"},{"issue":"13","key":"2026073103135912400_cit96","doi-asserted-by":"publisher","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent Advances in Pro-PROTAC Development\nto Address On-Target Off-Tumor\nToxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026073103135912400_cit97","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jconrel.2024.08.044","article-title":"Liver-Targeting\nChimeras as a Potential\nModality for the Treatment of Liver Diseases","volume":"374","author":"Chen","year":"2024","journal-title":"J. Controlled Release"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02127","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22095\/66299684\/acs.jmedchem.5c02127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/21\/22095\/66299684\/acs.jmedchem.5c02127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:14:05Z","timestamp":1785482045000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/21\/22095\/5235034\/Beyond-Inhibition-Recent-Advances-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":97,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,10,25]]},"published-print":{"date-parts":[[2025,11,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02127","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]}}}